Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | MLNR | O43193 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31664591 | 1.00 | BRD4 (0.36) | BRD4CREBBPHTR1AHTR7GRM2 | |
| SCHEMBL31664596 | 0.88 | BRD4 (0.35) | BRD4CREBBPIDH1KCNA5JAK2 | |
| SCHEMBL30782852 | 0.82 | BRD4 (0.34) | BRD4CREBBPHTR2CSLC6A4PDK2 | |
| SCHEMBL30782903 | 0.82 | BRD4 (0.34) | BRD4CREBBPHTR2CSLC6A4PDK2 | |
| SCHEMBL30782883 | 0.82 | PARP15 (0.35) | IDH1HTR2CKCNH2SLC6A4PDK2 | |
| SCHEMBL30782833 | 0.82 | PARP15 (0.35) | IDH1HTR2CKCNH2SLC6A4PDK2 | |
| SCHEMBL30782862 | 0.81 | GRM5 (0.34) | — | |
| SCHEMBL30782909 | 0.81 | GRM5 (0.34) | — | |
| SCHEMBL31664598 | 0.80 | HTR1A (0.38) | BRD4CREBBPHTR1AHTR7GRM2 | |
| SCHEMBL29923155 | 0.80 | BRD4 (0.36) | BRD4CREBBPHTR1AHTR7GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236602-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | CORETERRA THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236602-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PMP22, INA, SLC18A2 | BRD4 1824/4885CREBBP 1531/4885HTR1A 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.